Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07359846 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
A Phase 3 study of Severe Asthma, sponsored by Generate Biomedicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 786
- Enrollment target
- 2
- Study locations
NCT07359846 is a Phase 3 study of Severe Asthma that is actively recruiting participants, run by Generate Biomedicines. The registered enrollment target is 786 participants, below the 3,768-participant average among 9 other Severe Asthma trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07359846, a Phase 3 study of Severe Asthma, is actively recruiting participants, sponsored by Generate Biomedicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 786 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to receive either GB-0895 or placebo administered every 6 months over 52 weeks. Visit frequency: every 1-2 months after the first month.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GB-0895
Study Locations (2)
Florida
- Research Site 14 - Gainesville
- Research Site 01 - Tamarac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 786 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07359846
The ClinicalTrials.gov registry entry for NCT07359846 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 786 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,768-participant average among 9 other Severe Asthma trials with a reported enrollment target (79% lower). The listed sponsor is Generate Biomedicines, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07359846 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07359846 about?
NCT07359846 is a clinical study titled "A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)". The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to recei...
What is the current status of trial NCT07359846?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 786 participants. The study started on 2026-01-20. Estimated completion is 2029-01.
What conditions does trial NCT07359846 study?
This clinical trial studies the following conditions: Severe Asthma.
What interventions are being tested in trial NCT07359846?
The interventions under investigation include: Placebo (DRUG), GB-0895 (DRUG).
Who is sponsoring clinical trial NCT07359846?
This trial is sponsored by Generate Biomedicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07359846 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
RECRUITING · Phase 3
-
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
ACTIVE NOT RECRUITING · Phase 3
-
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
RECRUITING
-
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
RECRUITING · Phase 2
-
Phenotyping Asthma for Bronchial Thermoplasty
RECRUITING
-
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.